Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Corbus Pharmaceuticals Holdings (CRBP) Debt to Equity (2020 - 2024)

Corbus Pharmaceuticals Holdings has reported Debt to Equity over the past 4 years, most recently at -$2.31 for Q4 2023.

  • For Q4 2023, Debt to Equity fell 505.7% year-over-year to -$2.31; the TTM value through Dec 2023 reached -$2.31, down 505.7%, while the annual FY2023 figure was -$2.31, 505.7% down from the prior year.
  • Debt to Equity for Q4 2023 was -$2.31 at Corbus Pharmaceuticals Holdings, down from $0.12 in the prior quarter.
  • Over five years, Debt to Equity peaked at $1.19 in Q2 2023 and troughed at -$2.31 in Q4 2023.
  • A 4-year average of $0.27 and a median of $0.29 in 2021 define the central range for Debt to Equity.
  • On a YoY basis, Debt to Equity climbed as much as 402.35% in 2023 and fell as far as 505.7% in 2023.
  • Year by year, Debt to Equity stood at $0.42 in 2020, then tumbled by 34.82% to $0.27 in 2021, then surged by 110.05% to $0.57 in 2022, then tumbled by 505.7% to -$2.31 in 2023.
  • Business Quant data shows Debt to Equity for CRBP at -$2.31 in Q4 2023, $0.12 in Q3 2023, and $1.19 in Q2 2023.